Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 142 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infections, Pneumococcal Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

NCT00500266
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
68 Years and older
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
40
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 9, 2026, 11:57 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

NCT07660198
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Guntersville, Alabama • Fair Oaks, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652
View directory record Official record
Conditions
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 5 Years
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
21
States / cities
Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05420961
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
717 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

9-valent CRM 197 Pneumococcal

NCT00133549
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
Placebo, PNU-IMUNE®23, Nine-valent pneumococcal conjugate (PNCRM9)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
2
States / cities
Rochester, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 4 Interventional

Humoral Determinants of Immunity to Pneumococcal Infection

NCT00304382
View directory record Official record
Conditions
Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions
Prevnar, Pneumovax
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

NCT02124161
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions
13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

NCT00546572
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23vPS
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
70 Years and older
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
51
States / cities
Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 9, 2026, 11:57 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT07300267
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1), PCV20 (Stage 2)
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Months to 15 Months
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
14
States / cities
Madera, California • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05526716
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, QIV, Matching Placebo for V116
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
56
States / cities
Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 9, 2026, 11:57 PM EDT
Completed No phase listed Observational Results available

Impact of Prevnar 13 on Ear Infections in Children

NCT01272999
View directory record Official record
Conditions
Acute Otitis Media, Mastoiditis
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 9, 2026, 11:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunogenicity of PCV-7 Vaccine in VLBW Infants

NCT00273325
View directory record Official record
Conditions
Pneumococcal Infections, Streptococcus Pneumoniae, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 3 Months
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
10
States / cities
Birmingham, Alabama • Palo Alto, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

NCT04642079
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 17 Years
Enrollment
839 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
43
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 9, 2026, 11:57 PM EDT
Terminated No phase listed Observational

MISP 60528 Pneumococcal Vaccination

NCT04845945
View directory record Official record
Conditions
Heart Transplant Infection Prevention
Interventions
PCV15
Biological
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2

NCT00050726
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

NCT01654263
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
55 Years to 74 Years
Enrollment
884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
7
States / cities
Decatur, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 9, 2026, 11:57 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 9, 2026, 11:57 PM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 11:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Post-Vaccination Titers

NCT02726347
View directory record Official record
Conditions
Smokers, Elderly, Asthma, COPD, Recurrent Infections
Interventions
PPV-23
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
19 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 9, 2026, 11:57 PM EDT